Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Guaranteed Paid Placement
    • Cision Media Monitoring
    • Multichannel Amplification
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • All Multimedia

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Accessories
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High-Tech Security
      • Internet Technology
      • Nanotechnology
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Projections or Forecasts
      • Financing Agreements
      • Insurance
      • Investment Options
      • Joint Ventures
      • Mutual Funds
      • Offerings
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing/marketing agreements
      • New Products & Services
      • Obituary
      • Outsourcing Businesses
      • Overseas Real Estate (Non-US)
      • Personnel Announcements
      • Residential Real Estate
      • Small-Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Accessories
      • Computer Electronics
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Design Automation
      • Financial Technology
      • Mobile Devices/Apps
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Natural Gas Utilities
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Computer Accessories
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Computer Accessories
      • Computer Networks
      • Mobile Devices/Apps
      • Telecommunications
      • Telecommunications Carriers & Services
      • Telecommunications Equipment
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wine & Spirits
      • Beverages
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infectious Disease Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental Products & Services
      • European Government
      • Natural Disasters
      • Not-for-Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Children-related news
      • Disabled Persons
      • Diversity, Equity & Inclusion
      • Hispanic-oriented news
      • LGBTQ+
      • Religion
      • Senior Citizens
      • Veterans
      • Women-Related news
      • View All People & Culture

  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Multichannel Amplification
  • All Products
  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring Home
  • Send a Release
    • Chat

    • ALL CONTACT INFO
    • Contact Us


  • News Releases
  • Send a Release
  • Data Privacy
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • News Releases
  • Send a Release
  • Data Privacy
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Cision IR
  • SocialBoost
  • All Products
  • News Releases
  • Send a Release
  • Data Privacy
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • News Releases
  • Send a Release
  • Data Privacy

PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD
  • APAC - Traditional Chinese
  • Indonesia - Bahasa

Bened Life Inc. Logo

News provided by

Bened Life Inc.

25 Jan, 2024, 10:00 CST

Share this article

Share toX

Share this article

Share toX

SAN DIEGO, Jan. 25, 2024 /PRNewswire/ -- A recent study published in the Research in Autism Spectrum Disorders unveils groundbreaking solutions for neurodevelopmental disorders. This is the first double-blinded, randomized, placebo-controlled trial aimed at exploring the impact of a single probiotic strain on behavioral changes in preschool children aged 2.5–7 years with autism spectrum disorder (ASD), specifically targeting the gut-brain axis (GBA). The primary objective was to determine treatment effects by assessing using questionnaires related to ASD, mood, and activity symptoms at various time points with the intervention of Lactobacillus plantarum PS128 (PS128) probiotic.

Continue Reading

This trial enrolled 86 subjects and randomly allocated them in a 1:1 ratio to either the "PS128 early use group" (E group) or the "PS128 late use group" (L group). During the first stage, the E group received PS128, while the L group received placebo for 2 months. In the second stage, all subjects received PS128 for an additional 2 months. This trial demonstrated a significant reduction in anxious/depressed problems after taking two capsules of PS128 per day, providing a total of 6 × 1010 colony-forming units, for 2 months. The L group also showed notable improvement following 2 months of PS128 intervention in the second stage. These findings provide support for the notion that a brief 2-month intervention with a high dose of PS128 effectively improved certain internalizing issues in young children with ASD.

PS128 was proven to be a psychobiotic with neurotransmitter modulatory effects. Bened Life believes that PS128's positive impact on alleviating ASD-related symptoms is connected to changes in the metabolism of dopamine and serotonin in the brain. This belief is supported by previous studies showing that PS128 influences the metabolism of dopamine and serotonin in various rodent models. PS128 may also enhance the effect through its potential influence on microbial diversity.

Leveraging the Gut-Brain Axis (GBA) for Neurological Disorders Management

The intricate connection between the nervous system and the gastrointestinal tract is recognized as the GBA. It comprises the linkage between the central nervous system (brain), the enteric nervous system (gut), and the microbiome residing in the gut (microbiota), facilitated by the circulatory system, immune system, and the vagus nerve. The bidirectional communication between the brain and gut occurs through various channels, including nerve signals, immune molecules, hormones, and microbial metabolites. This sophisticated network underscores the dynamic interplay between neurological and gastrointestinal elements.

Individuals with neurodevelopmental conditions like ASD often experience imbalances of neurotransmitters, especially in happy hormones serotonin or dopamine activity, possibly resulting from gut dysbiosis. Taking a neurologically active probiotic like PS128 may offer potential assistance in managing these imbalances. Previous clinical trials involving children and adolescents with ASD suggest a potential reduction in ASD-related neurological behaviors with the use of PS128, along with improvements in anxiety levels, shared attention, and communication skills. Other findings indicate that PS128 could offer benefits in alleviating attention deficit hyperactivity disorder (ADHD)-related symptoms without causing adverse effects. This contrasts with many ADHD medications known for their side effects, suggesting a potential advantage of PS128 in avoiding such problems.

The decline in dopamine levels is associated with the aggregation of ⍺-synuclein in brain neurons that leads to the depletion of dopamine-producing neurons and the onset of motor symptoms in Parkinson's disease (PD). In addition to conventional treatment, individuals with PD experienced enhanced motor function and improved quality of life after supplementing with PS128 for 12 weeks. Notably, PS128 is considered safe to take alongside the usual dose of levodopa or other medications.

Furthermore, in a preliminary trial of PS128, there was a noteworthy amelioration in the severity of depression among individuals diagnosed with major depressive disorder.

Ongoing clinical trials are underway to uncover the unique position of neurobiotic PS128 in psychiatric disorders, seeking deeper insights to support and enhance mental well-being.

About Neurobiotics

Neurobiotics (or psychobiotics) offer a novel and low-risk alternative in providing comprehensive aid for individuals dealing with neurological conditions such as ASD and PD. Unlike common probiotics focused solely on digestion, neurobiotics encompass strains with neurological activity that support neurological health. Neurobiotic PS128 leverages the GBA to alleviate neurological symptoms associated with mood regulation, movement, learning, memory processes, and cognitive function. PS128 is safe for human supplementation, and no adverse events related to the PS128 intervention were found clinically.

About Bened Life

Bened Life is dedicated to providing science-backed, pharmaceutical-grade, gut-brain probiotics that support mental and neurological health. Neuralli Medical Probiotic, which contains the clinical dose of L. plantarum PS128, is a product attributed to the brand Bened Life. Visit benedlife.com to learn more about Neuralli.

Contact info
Name: Eva Lee
Email: [email protected] 

SOURCE Bened Life Inc.

Modal title

Also from this source

Bened Life Leads Advocacy Campaign Alongside Research Innovation During Neurodiversity Celebration Week

Bened Life Leads Advocacy Campaign Alongside Research Innovation During Neurodiversity Celebration Week

Bened Life, a pioneering biotechnology company dedicated to advancing mental and neurological health, is announcing an international donation...

More Releases From This Source

Explore

Supplementary Medicine

Supplementary Medicine

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

News Releases in Similar Topics

Contact Cision

  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Careers
  • Accessibility Statement
  • APAC – Simplified Chinese
  • APAC
  • APAC - Traditional Chinese
  • Arabic
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
  • Vietnam

My Services

  • All New Releases
  • Platform

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
[email protected]
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
  • Accessibility
Copyright © 2025 Cision US Inc.